Therapeutic equivalence? [Design Issues]

posted by bjkim97  – Korea / Seoul, 2011-03-03 13:37 (5592 d 08:20 ago) – Posting: # 6693
Views: 8,736

Thank you for reply MR Dan

But no one expected the authorities of your country permit did not have?
As you know yourself, FDA recommend that patients with Imatinib to look at is.
Not available as well as healthy adults, but not the PK DATA, Issue, did not we.

Yet I did not proceed too many questions to be asked.
We look forward to in kind. ^_^;;

Thank you so much Dan
BJ


Edit: Full quote removed. Please delete anything from the text of the original poster which is not necessary in understanding your answer; see also this post! [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
135 visitors (0 registered, 135 guests [including 34 identified bots]).
Forum time: 22:57 CEST (Europe/Vienna)

Scientists often have a naïve faith that
if only they could discover enough facts about a problem,
these facts would somehow arrange themselves
in a compelling and true solution.    Theodosius Dobzhansky

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5